Volume 5.16 | May 9

Prostate Cell News 5.16 May 9, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Talin1 Phosphorylation Activates β1 Integrins: A Novel Mechanism to Promote Prostate Cancer Bone Metastasis
Using knockdown experiments, scientists first demonstrated that talin1, but not talin2, is important in ß1 integrin activation. They next showed that talin1 S425 phosphorylation, but not total talin1 expression, correlates with metastatic potential of prostate cancer cells. [Oncogene] Abstract
Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Bone-Induced c-Kit Expression in Prostate Cancer: A Driver of Intraosseous Tumor Growth
Researchers showed that c-kit expression promotes migration and invasion of prostate cancer (PCa) cells. They also found that c-kit expression in PCa cells parallels BRCA2 downregulation. [Int J Cancer] Abstract

Effects of Functional Genetic Polymorphisms in the CYP19A1 Gene on Prostate Cancer Risk and Survival
Scientists investigated the functions of CYP19A1 polymorphisms and their associations with prostate cancer risk and clinical outcome. The functions of single nucleotide polymorphisms were determined by reporter gene assays in PC3 and DU145 cell lines. [Int J Cancer] Abstract

The Combination of the Prodrugs Perforin-CEBPD and Perforin-Granzyme B Efficiently Enhances the Activation of Caspase Signaling and Kills Prostate Cancer
Researchers showed that the combination of a perforin (PF)-CCAAT/enhancer binding protein delta (CEBPD) prodrug and a PF-granzyme B prodrug showed an additive effect in triggering the apoptotic pathway and enhancing apoptosis in prostate cancer cells. [Cell Death Dis] Full Article

Pigment Epithelium-Derived Factor Expression Prolongs Survival and Enhances the Cytotoxicity of Low-Dose Chemotherapy in Castration-Refractory Prostate Cancer
Scientists report the anti-tumor effect of the angio-inhibitory pigment epithelium-derived factor in the metastatic LNCaP-derivative castration-refractory prostate cancer CL1 model and explore PEDF anti-neoplasic efficacy in combination with low-dose chemotherapy. [Cell Death Dis] Full Article

COX-2 Inhibitors Arrest Prostate Cancer Cell Cycle Progression by Down-Regulation of Kinetochore/Centromere Proteins
Treatment with the COX-2 inhibitors celecoxib and CAY10404 or knockdown of COX-2 significantly inhibited prostate cancer cell proliferation. [Prostate] Abstract

NPM1 Silencing Reduces Tumor Growth and MAPK Signaling in Prostate Cancer Cells
To better understand nucleophosmin (NPM1) functions in prostate cancer cells, researchers sought to characterize its impact on prostate cancer cells behavior and decipher the mechanisms by which it may act. They showed that NPM1 favors prostate tumor cell migration, invasion and colony forming. [PLoS One]
Full Article

Distinct Phenotypes of Human Prostate Cancer Cells Associate with Different Adaptation to Hypoxia and Pro-Inflammatory Gene Expression
Scientists explored how different features, including differentiation and aggressiveness, of prostate tumor cell lines impact on the hypoxic remodeling of pro-inflammatory gene expression and malignancy. [PLoS One]
Full Article

AKT and AMPK Activation after High-Fat and High-Glucose In Vitro Treatment of Prostate Epithelial Cells
Investigators analyzed the proliferation profile of nonmalignant human prostate epithelial cells after exposure to elevated levels of fat and glucose. [Horm Metab Res] Abstract

CLINICAL RESEARCH

A Randomized Phase II Study of Cediranib Alone versus Cediranib in Combination with Dasatinib in Docetaxel Resistant, Castration Resistant Prostate Cancer Patients
Phase II studies of cediranib and dasatinib in castration-resistant prostate cancer (CRPC) have shown single agent activity. Docetaxel-pretreated CRPC patients were randomized to arm A: cediranib alone versus arm B: cediranib plus dasatinib given orally on four-week cycles. [Invest New Drugs] Abstract

The Impact of Multiparametric Pelvic Magnetic Resonance Imaging on Risk Stratification in Patients With Localized Prostate Cancer
Scientists determined the impact of multiparametric magnetic resonance imaging of the prostate on established risk stratification criteria in patients with clinically localized adenocarcinoma of the prostate. [Urology] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
 
REVIEWS
The Link between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
Resistance to the latest advanced prostate cancer therapies, including abiraterone and enzalutamide, is associated with increased expression of constitutively active androgen receptor splice variants. The authors examine androgen receptor splice variants as an alternative mechanism by which prostate cancer becomes resistant to androgen receptor-directed therapy. [Horm Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer
Astellas Pharma Inc. and Medivation Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy. [Astellas Pharma Inc.] Press Release

Prostate Cancer Foundation Announces Over $8.4 Million Donation to Advance Prostate Cancer Research
The Prostate Cancer Foundation (PCF) has received over $8.4 million from its partner Movember raising vital funds and awareness for men’s health. PCF will allocate the over $8.4 million to find better treatments and ultimately a cure, by funding first in field research. [The Prostate Cancer Foundation] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW International Congress on Stem Cells and Tissue Formation
July 8-11, 2014
Dresden, Germany

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

NEW Associate Research Scientist – Prostate Tumor Initiation and Formation of Cancer Stem Cells (Herbert Irving Comprehensive Cancer Center-CUMC)

NEW PhD Student Position – Development of Phellinus linteus as an Anti-Prostate Cancer Drug (Sahlgrenska Academy)

Research Associate – Prostate Cancer (University of Cambridge)

Postdoctoral Researcher – Therapeutic Targets for Cancer Treatment (Sanford Burnham Medical Research Institute)

PhD Position – 3D Cell Culture & Microfluidics: New Insights in Prostate Cancer (CEA French Atomic and Alternative Energies Commission)

Postdoctoral Position – Nuclear Import Mechanisms for the Androgen Receptor and Its Variants (Cornell University)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Studentship – Targeting WW Domain Function in Ubiquitin Ligases Overexpressed in Prostate Cancer (University of East Anglia)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us